American College of Clinical Pharmacy
      Search      Cart

GI/Liver/Nutrition PRN Focus Session -- GI/Liver/Nutrition Potpourri: Alcohol Use, Absorption after Bariatric Surgery, and IBS/IBD Updates

Sunday, October 08, 2017 from 4:00 PM to 5:30 PM MST at Phoenix Convention Center North Building Street Level: Meeting Room 125

Available for 1.50 hours of CPE credit
Activity Number: 0217-0000-17-144-L01-P
Activity Type: A Knowledge-Based Activity

  • Moderator: Johnathan Voss, Pharm.D.

Kicking the Liver While its Down - Promoting Abstinence and Treating Alcohol Withdrawal in Liver Disease
4:00 PM

  • Speaker: Jennifer Twilla, Pharm.D.
    Methodist University Hospital, University of Tennessee, Memphis, Tennessee
    View Biography

Learning Objectives
1. Discuss the epidemiology and pathophysiology of alcohol-induced liver failure.
2. Appraise the evidence concerning alcohol use in patients with liver disease.
3. Identify strategies for promoting abstinence and preventing withdrawal in patients with alcohol-induced liver disease using patient cases.
A Growing Problem: Absorption Issues Related to Bariatric Surgery
4:30 PM

  • April N. Smith, Pharm.D., BCPSSpeaker: April N. Smith, Pharm.D., BCPS
    Associate Professor, Creighton University School of Pharmacy & Health Professions, Omaha, Nebraska
    View Biography

Learning Objectives
1. Discuss different bariatric surgery techniques and their impact on medication absorption.
2. Identify micronutrients with altered absorption in patients with a history of bariatric surgery.
3. Develop strategies for managing medication and micronutrient absorption issues related to bariatric surgery using example patient cases.
Taming the Irritated and Inflamed - Treatment Updates in IBS and IBD
5:00 PM


Learning Objectives
1. Discuss the most recent guidelines for irritable bowel syndrome and inflammatory bowel disease.
2. Identify the preferred treatment approaches to irritable bowel syndrome and inflammatory bowel disease.
3. Discuss the impact of nutrition on the management of irritable bowel syndrome.
4. Compare and contrast biological agents used in the treatment of inflammatory bowel disease and their related biosimilar agents.